TABLE 3.
Effect Size Estimates for Changes in Outcome Measures at 3- and 6-Months
| 3-Mo Change | 6-Mo Change | |||
|---|---|---|---|---|
|
|
|
|||
| Measure | Effect Sizea | 95% CI | Effect Sizea | 95% CI |
|
| ||||
| Clinical | ||||
| HAM-D | −0.02 | (−0.38, 0.33) | −0.08 | (−0.45, 0.29) |
| GDS | 0.19 | (−0.17, 0.55) | 0.29 | (−0.09, 0.67) |
| CD-RISC | −0.09 | (−0.45, 0.27) | −0.06 | (−0.44, 0.31) |
| SF-36 General Health | −0.23 | (−0.59, 0.13) | −0.29 | (−0.76,−0.01) |
| Cognitive Domains | ||||
| Delayed recall | 0.26 | (−0.11, 0.63) | 0.17 | (−0.21, 0.55) |
| Attention/Executive function | 0.13 | (−0.24, 0.49) | 0.29 | (−0.09, 0.68) |
| Language | −0.35 | (−0.72, 0.02) | −0.35 | (−0.73, 0.03) |
a
Effect sizes are Cohen’s d estimates. For HAM-D and GDS, where a higher score represents worse symptoms, a positive value indicates a better treatment effect of TCC versus HEW; for CD-RISC, SF-36 and cognitive domains where a higher score represents better resilience/performance, a negative value indicates a better treatment effect of TCC versus HEW.